|

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients

RECRUITINGN/ASponsored by University of Texas Southwestern Medical Center
Actively Recruiting
PhaseN/A
SponsorUniversity of Texas Southwestern Medical Center
Started2020-06-15
Est. completion2028-08-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04164173

Summary

The purpose of this prospective randomized clinical trial is to evaluate three different types of hyperinflation respiratory therapies, Intermittent Positive Pressure Breathing (IPPB), Intermittent positive end expiratory pressure (EzPAP), Metaneb. Investigators will examine which hyperinflation therapy provides better lung expansion and may improve lung recovery after surgery.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Age 18 years and older
2. Admitted to Cardiovascular ICU (CVICU) after coronary artery bypass grafting (CABG), isolated valve repair/replacement, or CABG + valve repair/replacement
3. Cardiac surgery performed via median sternotomy

Exclusion Criteria:

1. BMI\>40
2. Refusal to be consented
3. Prior or current lung transplant patients

Conditions3

Heart DiseasePostoperative ComplicationsPulmonary Disease

Locations1 site

UT Southwestern Clements University Hospital
Dallas, Texas, 75390
Cheryl Mansir, RT214/633-4791Cheryl.Mansir@UTSouthwestern.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.